Literature DB >> 17001874

[What can we learn from genes responsible for familial forms of Parkinson's disease?].

Alexis Brice1.   

Abstract

During the past decade, the identification of several genes responsible for monogenic forms of Parkinson's disease has greatly increased our knowledge of the pathophysiological mechanisms of this disease. The alpha-synuclein gene, involved in very rare forms with autosomal dominant transmission, encodes a protein which is a major component of Lewy bodies, the histopathological hallmark of the disease. The Parkin gene, responsible for a significant number of cases with early onset, encodes an E3 ubiquitin-ligase, supporting the involvement of the ubiquitin-proteasome pathway in Parkinson's disease. Finally, mutations in the LRRK2 gene, which codes for a kinase with unknown substrates, accounts for a substantial fraction of autosomal dominant forms, particularly in North Africa. The study of these genes shows that the formation of Lewy bodies is not mandatory for the degeneration of dopaminergic neurons in Parkinson's disease. It remains to be determined whether the products of the genes are implicated in the same metabolic path way.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001874

Source DB:  PubMed          Journal:  Bull Acad Natl Med        ISSN: 0001-4079            Impact factor:   0.144


  2 in total

1.  Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism.

Authors:  Mali Jiang; Yair Porat-Shliom; Zhong Pei; Yong Cheng; Lan Xiang; Katherine Sommers; Qing Li; Frank Gillardon; Bastian Hengerer; Cynthia Berlinicke; Wanli W Smith; Donald J Zack; Michelle A Poirier; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2010-04-19       Impact factor: 5.372

2.  Trehalose Inhibits A53T Mutant α-Synuclein Overexpression and Neurotoxicity in Transduced PC12 Cells.

Authors:  Juan Zhao; Xiuling Zhi; Luanfeng Pan; Ping Zhou
Journal:  Molecules       Date:  2017-08-08       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.